| Product |
Drug |
Indication |
Current status |
| ABI-007 (Abraxane®) |
Albumin-paclitaxel nanoparticle |
Oncology |
Marketed |
| 99mTc-Albures |
99mTc –aggregated albumin |
Oncology |
Marketed |
| 99mTc-Nanocoll |
99mTc –aggregated albumin |
Oncology |
Marketed |
| Vasovist® |
Albumin-binding Gadolinium (III) complex |
Oncology |
Marketed |
| B-22956/1 |
Albumin-binding Gadolinium (III) complex |
Oncology |
Marketed |
| Levenir® |
Albumin-binding fatty acid derivative of insulin |
Diabetes |
Marketed |
| Liraglutide (Victoza®) |
Albumin-binding fatty acid derivative of GLP-1 |
Diabetes |
Marketed |
| Albuferon® |
Albumin-fusion protein of interferon-α-2b |
Hepatitis C |
Phase III |
| AT-103 (Ozoralizumab) |
Albumin-binding nanobody directed against human TNF-α |
Rheumatology |
Phase II |
| INNO-206 |
Albumin binding prodrug of doxorubicin |
Oncology |
Phase II |
| ABI-008 |
Albumin-docetaxel nanoparticle |
Oncology |
Phase II |
| MTX-HSA |
Methotrexate albumin conjugate |
Oncology |
Phase I/II |
| MM-111 |
Albumin fusion protein directed against ErbB2 and ErbB3 |
Oncology |
Phase I/II |
| AFL-HSA |
Albumin conjugate of aminofluorescein |
Oncology |
Phase I/II |
| CjC-1134-PC |
Albumin conjugate of exendin-4 |
Diabetes |
Phase I/II |
| ABI-009 |
Albumin-rapamycin nanoparticle |
Oncology |
Phase I |
| ABI-010 |
Albumin nanoparticle with a HSP90 inhibitor |
Oncology |
Phase I |
